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The Pharmacodynamics of Pentobarbital Following FK 506 Therapy 
K. Habucky, R. Venkataramanan. R. Xiaoshan. V.S. Wart>!. J.J. Fung. and T.E. Starzl 
I MMUNOSUPPRESSANTS are administered chroni-
cally with other pharmacological agents such as anti-
hypertensives. antifungals. antibiotics. and steroids. Pre-
liminary studies indicate that FK 506 significantly alters 
hepatic drug metabolism. I- 3 Alterations in hepatic metab-
olism of a coadministered drug may affect the pharmaco-
kinetics and pharmacodynamics of the other drug. Thus 
far. no studies have investigated the effect of FK 506 
administration on the pharmacological effect of a concur-
rently administered drug. The objective of this study was 
to investigate the effect of various routes of administration 
and different administration regimens of FK 506 on the 
pharmacodynamics of pentobarbital. 
STUDY DESIGN 
Male Wistar rats (N = 42) were randomized into one of six 
treatment groups. Group I received intramuscular saline 
(0.2 mL) for 7 days. Group II was treated with intramus-
cular FK 506 (1.3 mglkg) for 7 days and group III received 
a single intramuscular dose of FK 506 (1.3 mglkg). Group 
IV received oral saline <0.9 mL) for 7 days. while group V 
was treated with oral FK 506 (4 mgtkg) for 7 days. Group 
VI received a single oral dose of FK 506 00 mglkg). All 
animal body weights were kept close together at the start 
of the treatment due to reported age differences in drug 
metabolism and response. 4 One day prior to the pentobar-
bital administration. jugular catheters were placed in all 
animals under light ether anesthesia. The animals were 
fasted overnight and for up to 4 hours after pentobarbital 
Fig 1. PentObarbital sleep 
times: Group I. 1M control; group 
II. 1M FK 506 (1.3 mglkg for 7 
days); group Ill. 1M FK 506 (sin-
gle dose 1.3 mglkg); group IV. 
PO control: group V. PO FK 506 
(4 mglkg for 7 days); and group 
VI, PO FK 506 (single dose 10 
mglkg). 
administration. On the study day. blood (0.4 mL) was 
drawn to determine the trough FK 506 concentration. and 
2 hours after the designated treatment. an IV dose of 
pentobarbital (30 mglkg) was administered. The animals 
were placed on isothermal pads and a blinded observer 
recorded the sleep time. The sleep time was determined 
when the animal regained his righting reflex twice within a 
period of 10 seconds. A blood sample was drawn (0.3 ml) 
at the time the animals awoke to determine the plasma 
pentobarbital concentration and liver function tests. 
ANALYSIS 
FK 506 concentrations in the plasma were measured bv 
ELISA.s Pentobarbital concentrations were measured bv 
high pressure liquid chromatography. b The liver functlo~ 
tests were performed by standard methods. 
The various parameters in different groups were com-
pared by analysis of variance. Dunnett's procedure was 
used to compare the various groups to the control group. A 
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. ': __ K~-DKDI PENTOBARBITAL FOLLOWING FK 506 
~ Table 1. Plesma Conc:entnItion of Pentobarbital at Wake Up 
Group Concentration (mcgtmL) 
9,7 = 2.2 
10.7:!: 2.8 
III 10.3:!: 1,6 
IV 11.0 = 1.9 
V 9.7:!: 3.0 
VI 10.7:!: 2.5 
P value of less than .05 was considered statisticalh' signif-
icant. 7 
RESULTS AND DISCUSSION 
There were no significant differences in the liver or kidney 
function tests in all animals. indicating that FK 506 treat· 
ment did not alter liver and kidney function in rats. 
Sleep times are shown in Fig I. There was no statistical 
difference in the sleep time for animals treated with oral 
FK 506: however. animals which receIved chronic intra-
muscular FK 506. on average. slept 69 minutes longer as 
compared to the control rats. There was no significant 
difference in the concentration of pentobarbital at the time 
the animals awoke. indicating that FK 506 treatment did 
not alter the sensitivity of the central nervous system to 
the effect of pentobarbital (Table I). 
The trough FK 506 after oral and intramuscular treat-
ment are reported in Table 2. There was no significant 
difference between the group which received a high single 
oral dose of FK 506 (10 mglkg) and the group which 
received smaller mUltiple oral doses of FK 506 (4 mgtkg for 
7 days). indicating potential accumulation of FK 506 after 
chronic therapy. Although the concentration of FK 506 
was higher in the oral treatment groups as compared to the 





FK 506 Concentration (ngrmL) 
9.3 = 2.0 
3.7:!: 2.5 
14,7 :!: 9.0 
11.6:!: 6.5 
2801 
intramuscular grouP. there was no change in pentobarbital 
sleep time when FK 506 was administered orally. This may 
be partially attributable to the marked fluctuations In the 
concentration of FK 506 during a dosing interval after oral 
administration. whereas the intramuscular preparation 
provides a sustained release of FK 506 during the dosing 
interval. It is also possible that FK 506 measured after 
intramuscular administration is primarily parent FK 506. 
while following oral administration. more metabolites are 
produced during the first pass through the liver and the gut 
which are also measured by the ELISA assay. These 
metabolites. perhaps. do not alter hepatic metabolism. 
CONCLUSIONS 
The pharmacodynamics of pentobarbital was affected after 
chronic intramuscular treatment with FK 506. Since the 
concentration of pentobarbital was the same at the time the 
animals awoke in the control group and the chronic intra-
muscular group. FK 506 does not appear to have altered 
the sensitivity of the ammals to pentobarbital. Although 
FK 506 is a p~tent inhibitor of hepatic drug metabolism. as 
shown by in vitro and in vivo animal studies. chronic oral 
use of FK 506 in patients is likely to minimally alter hepatic 
metabolism at clinically relevant doses. Future studies will 
evaluate the pharmacokinetics of pentobarbital to establish 
potential changes in the disposition of pentobarbital fol-
lowing various FK 506 treatments. 
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